// App-Quantinova.ai

e14098 : Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.

Researchers

Presenter

  • R Donald Harvey

Principal Investigators

  • Nicolas Isambert

  • Saeed Rafii

  • Johan F. Vansteenkiste

  • Paul A. Dickinson

  • Khanh Bui

  • Doris Weilert

  • Karen So

  • Karen Thomas

  • Karthick Vishwanathan

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Center Georges-Francois Leclerc, Dijon, France

  • Sarah Cannon Research Institute, London, United Kingdom

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Seda Pharmaceutical Development Services, Alderley Edge, United Kingdom

  • Quantitative Clinical Pharmacology, AstraZeneca, Waltham, MA

  • Quintiles Inc., Overland Park, Leawood, KS

  • Biostatics and Informatics, AstraZeneca, Macclesfield, United Kingdom

Locations

  • United States

  • France

  • Belgium

  • United Kingdom

Companies

  • Quintiles and IMS He

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Rosuvastatin

  • Simvastatin

  • Tagrisso

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT02197234

  • NCT02317016

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved